Skip to main content
TipRanks
Go Ultimate75% OFF

Addex Therapeutics (ADXN) AI Stock Analysis

86 Followers
ADXN

Addex Therapeutics

(NASDAQ:ADXN)

Select Model
Rating:44Neutral
Price Target:$5.00▲(23.15% Upside)
Action:reiterated
Date:11/13/26

The score is primarily constrained by very weak financial performance, including declining revenue, ongoing losses, and negative cash flow. Positive technical momentum and encouraging pipeline progress provide some support, but overbought conditions, negative earnings-based valuation, and financing dependence keep the overall score low.

Positive Factors
Broad GPCR pipeline and regained rightsRegaining full rights increases Addex’s control over development, partnering, and indication selection for the GABAB PAM platform. The broader candidate portfolio creates multiple paths to value creation across substance use disorders, cough, pain, overactive bladder, and neurodevelopmental disorders.
Negative Factors
Persistent cash burn and lossesOngoing negative operating and free cash flow means Addex is not yet funding research and development from internally generated cash. Continued losses can consume available resources, increase reliance on external capital, and constrain the pace or breadth of pipeline advancement.

Addex Therapeutics (ADXN) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%ADXN-52.90%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$5.00M
Dividend Yield
―
Average Volume (3M)
518.40K
Price to Earnings (P/E)
-0.7
Beta (1Y)
1.37
Revenue Growth
-45.76%
EPS Growth
-3.77%
Country
US
Employees
3
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Addex Therapeutics Business Overview & Revenue Model

Company Description

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core...

How the Company Makes Money

Addex Therapeutics primarily makes money through partnering and collaboration arrangements rather than commercial product sales (as a clinical-stage company). Its revenue model typically consists of: (1) upfront payments received when entering licens...

Addex Therapeutics Earnings Call Summary

Earnings Call Date:Sep 28, 2026(Q2-2026)|% Change Since:11.23%|Next Earnings Date:May 20, 2020
Earnings Call SentimentPositive

The call was predominantly positive, highlighting a $2.8 million financing, cash runway into Q4 2027, regained rights to the GABAB PAM platform, multiple advancing preclinical and clinical programs, and encouraging chronic cough and substance use disorder data. Offsetting factors included the CHF 0.8 million half-year cash balance, CHF 1.2 million of operating cash use, a stable CHF 3.4 million net loss, increased share of Neurosterix losses, and the need to secure financing before advancing certain programs.

Positive Updates

Balance Sheet Strengthened and Runway Extended
Addex raised $2.8 million through its ATM facility in Q3, providing a cash runway into Q4 2027.

Negative Updates

Limited Cash Balance at Half-Year End
Addex ended H1 2026 with CHF 0.8 million in cash, compared with CHF 1.6 million as of December 31, 2026, a decrease of CHF 0.8 million primarily due to operating costs, partially offset by the sale of treasury ADSs.

Company Guidance

Addex said the GABAB PAM substance use disorder candidate is ready for IND filing and phase I clinical trials, with the next milestone being the filing of an IND, while IND enabling studies for the chronic cough program are “planned and ready to start subject to securing financing”; it expects phase I data from Neurosterix’s NTX-253 program in Q4 this year, NTX-529 IND-enabling studies should start shortly, NTX-819 is expected to complete IND-enabling studies in the coming months, and it continues to prepare dipraglurant for phase II in post-stroke recovery. The company said it raised $2.8 million in Q3 through its ATM facility, providing cash runway into Q4 2027, and that patents filed in 2024, if granted, are expected to expire in 2044.

Addex Therapeutics Financial Statement Overview

Summary

Minimal and declining revenue, persistent losses, negative cash flow, and continued capital consumption are severe weaknesses. Very low debt and reduced losses and cash burn provide limited support, but the financial profile remains at the minimum score range.

Income Statement

27Negative

Balance Sheet

35Negative

Cash Flow

32Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Dec 2022Dec 2021
Income Statement
Total Revenue47.57K29.97K404.10K1.61M1.42M2.92M
Gross Profit-13.68K29.97K404.10K1.61M1.42M2.92M
EBITDA-5.72M-6.83M-4.65M-2.19M-10.45M-14.94M
Net Income-6.86M-6.73M7.06M-10.56M-20.80M-15.35M
Balance Sheet
Total Assets3.48M6.37M10.68M4.64M8.28M22.54M
Cash, Cash Equivalents and Short-Term Investments767.33K1.64M3.35M3.87M6.96M20.50M
Total Debt77.50K34.73K41.99K344.34K373.13K482.01K
Total Liabilities1.57M1.60M1.00M3.50M3.37M5.61M
Stockholders Equity1.91M4.77M9.68M1.15M4.91M16.93M
Cash Flow
Free Cash Flow-2.38M-2.08M-5.37M-8.00M-16.44M-14.74M
Operating Cash Flow-2.38M-2.08M-5.37M-7.99M-16.44M-14.71M
Investing Cash Flow51.03K-650.08K4.65M-6,8422,972-30.31K
Financing Cash Flow800.71K1.13M104.92K5.26M3.10M16.40M

Addex Therapeutics Technical Analysis

Technical Analysis SentimentPositive
Last Price4.06

Price Trends

50DMA3.19Positive
100DMA4.28Negative
200DMA5.55Negative

Market Momentum

MACD0.15Negative
RSI59.00Neutral
STOCH45.92Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADXN, the sentiment is Positive. The current price of 4.06 is above the 20-day moving average (MA) of 3.11, above the 50-day MA of 3.19, and below the 200-day MA of 5.55, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 59.00 is Neutral, neither overbought nor oversold. The STOCH value of 45.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ADXN.

Addex Therapeutics Risk Analysis

Addex Therapeutics disclosed 54 risk factors in its most recent earnings report. Addex Therapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We were an "emerging growth company" for the financial reporting published until December 31, 2025 and it is possible that investors have found or will continue to find shares or our ADSs less attractive.Q4, 2025
2.The value of our ADSs may be driven by the release of preclinical and clinical studies led by Neurosterix GroupQ4, 2024
3.Our Partner Janssen terminated the development of our drug candidate in epilepsy and returned to us this drug candidateQ4, 2024

Addex Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ADXN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
XBIOXBIO46Neutral$3.89M-1.05-58.96%―3.50%22.76%
NCNANCNA44Neutral$4.49M-0.22-51.04%――97.82%
ADXNADXN44Neutral$4.89M-0.69-172.76%―-45.76%-3.77%
KPRXKPRX41Neutral$5.44M-0.44-82.06%――-18.90%
HCWBHCWB38Underperform$1.73M-0.01-142.16%―707.02%70.52%

* Healthcare Sector Average

Performance Comparison

-50%0%50%ADXNKPRXXBIONCNACELZHCWBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ADXN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ADXNAddex Therapeutics Ltd (ADR)4.06-4.90-54.68%
KPRXKiora Pharmaceuticals, Inc.1.23-0.84-40.58%
XBIOXenetic Biosciences, Inc.1.66-0.91-35.41%
NCNANucana Plc0.93-2.38-71.84%
CELZCreative Medical Technology Holdings, Inc.0.53-2.52-82.69%
HCWBHcw Biologics, Inc.0.77-13.69-94.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026